Wall Street analysts are bullish on recently launched health-care technology stock Tempus AI . By combining a patient's molecular, clinical, and imaging data with its AI platform, Tempus delivers personalized therapy decisions," he wrote. Tempus AI debuted at the Nasdaq on June 14, closing at $40 after pricing its initial public offering at $37. Last month, investment management firm SoftBank announced it had invested about $200 million in Tempus AI before its Nasdaq listing. Since its debut, Tempus AI stock has slipped 10% from its IPO price.

---

Persons: Michael Ryskin, SoftBank, America's Ryskin, Ryskin, JPMorgan's Rachel Vatnsdal, William Blair, Morgan Stanley, Tejas Savant, TD Cowen, Dan Brennan Organizations: Bank of America, Tempus, Nasdaq, America's, Precision Oncology, Loop Capital Locations: Stifel, Needham